Novo Nordisk’s stock took a hit after an Alzheimer’s trial for semaglutide failed to meet its main cognitive goal, sending shares to a four-year low. The company, known for its GLP-1 drugs, has faced a tough year with a 45% drop in its stock price due to various factors. Novo reported mixed Q3 earnings and narrowed its outlook for fiscal 2025. Analysts have reacted negatively to the trial failure, with Morgan Stanley and HSBC downgrading the stock. However, UBS maintains a more positive view. Wall Street consensus remains moderately bullish, with a mean price target of $54.40. Despite setbacks, Novo remains strong long-term with its pipeline and cash holdings.

Read more at Yahoo Finance: Should You Buy the Massive Dip in Novo Nordisk Stock?